Examination of How the Duration of Fasting and Temporary Stopping of Zenagamtide Dosing Affect the Amount of Food Left in the Stomach in Adults With Overweight or Obesity, With or Without Type 2 Diabetes
Investigation of the Effect of Fasting Duration and Temporary Withholding of Subcutaneous Administration of Zenagamtide on Retained Gastric Contents in Participants With Overweight or Obesity, With or Without Type 2 Diabetes
The purpose of this clinical study is to find out how the duration of fasting (not eating or drinking, except for water) and pausing of treatment with zenagamtide medication affect the amount of food and liquid left in the stomach of people using zenagamtide.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Novo Nordisk
- Telefonnummer: (+1) 866-867-7178
- E-mail: clinicaltrials@novonordisk.com
Studiesteder
-
-
California
-
Cypress, California, Forenede Stater, 90630
- Altasciences Clinical LA, Inc.
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male or female (sex assigned at birth, inclusive of all gender identities).
- Age 18 and older at the time of signing the informed consent.
- Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator.
For participants with type 2 diabetes (T2D)
- Diagnosed with type 2 diabetes (T2D) more than (>) 180 days before screening.
- No treatment with oral anti-diabetic drugs except metformin. Treatment with metformin should be stable (dose and dosing frequency) for at least 90 days before screening.
Exclusion Criteria:
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.
- Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders as judged by the investigator.
- Diagnosed with or suspected to suffer from gastroparesis, hiatal hernia or severe gastro-oesophageal reflux diseases with daily symptoms and/or when in supine position.
- Use of other medications known to affect the motility of the stomach.
- Inability to lie in the right lateral decubitus position for gastric ultrasonography.
For participants without T2D - Glycated haemoglobin (HbA1c) more than or equal to (≥) 6.5 percent (%) [48 millimoles per mole (mmol/mol)] at screening.
For participants with T2D
- HbA1c ≥ 10.5 % (91 mmol/mol) at screening.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Zenagamtide
Participants will receive zenagamtide once weekly subcutaneously (s.c.). |
Zenagamtide will be administered subcutaneously using PDS290 pre-filled pen-injectors in one of the body parts: thigh, abdomen or upper arm. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on visit 2 day 1 (V2D-1) and V19D2
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on visit 2 day 1 (V2D-1) and V19D2
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a liquid meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
|
Gastric volume after fasting following a liquid meal 1 day after dosing of s.c. zenagamtide once weekly
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
Measured as milliliter per kilogram (mL/kg) |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
|
Gastric volume after fasting following a solid, high-fat meal 1 day after dosing of s.c. zenagamtide once weekly
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2
|
Measured as mL/kg |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2
|
|
Presence of solids in the stomach (antrum grade 'solid') after fasting following a liquid meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
|
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2
|
|
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 4 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
|
Gastric volume after fasting following a solid, high-fat meal 4 days after dosing of s.c. zenagamtide once weekly
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
Measured as mL/kg |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
|
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 4 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
|
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 7 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
|
Gastric volume after fasting following a solid, high-fat meal 7 days after dosing of s.c. zenagamtide once weekly
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
Measured as mL/kg |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
|
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 7 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NN9490-8698
- U1111-1336-6870 (Anden identifikator: World Health Organization (WHO))
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .